195 related articles for article (PubMed ID: 15500387)
1. Telmisartan - killing two birds with one stone.
Doggrell SA
Expert Opin Pharmacother; 2004 Nov; 5(11):2397-400. PubMed ID: 15500387
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
Younis F; Kariv N; Nachman R; Zangen S; Rosenthal T
Clin Exp Hypertens; 2007 Aug; 29(6):419-26. PubMed ID: 17729058
[TBL] [Abstract][Full Text] [Related]
3. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
[TBL] [Abstract][Full Text] [Related]
4. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Janke J; Clasen R; Unger T; Kintscher U
Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.
Younis F; Oron Y; Limor R; Stern N; Rosenthal T
Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
[TBL] [Abstract][Full Text] [Related]
10. [PPARgamma-activating properties of angiotensin receptor blockers].
Ando H; Fujimura A
Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
[No Abstract] [Full Text] [Related]
11. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Tuck ML
Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
[TBL] [Abstract][Full Text] [Related]
13. Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
Fujimura A; Ushijima K; Ando H
Hypertens Res; 2013 Feb; 36(2):183. PubMed ID: 23190691
[No Abstract] [Full Text] [Related]
14. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.
Li L; Luo Z; Yu H; Feng X; Wang P; Chen J; Pu Y; Zhao Y; He H; Zhong J; Liu D; Zhu Z
Diabetes; 2013 Mar; 62(3):762-74. PubMed ID: 23238297
[TBL] [Abstract][Full Text] [Related]
17. Are the pleiotropic effects of telmisartan clinically relevant?
Rizos CV; Elisaf MS; Liberopoulos EN
Curr Pharm Des; 2009; 15(24):2815-32. PubMed ID: 19689352
[TBL] [Abstract][Full Text] [Related]
18. Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Doggrell SA
Curr Opin Investig Drugs; 2005 Mar; 6(3):242-4. PubMed ID: 15816499
[No Abstract] [Full Text] [Related]
19. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]